Tympanostomy-Tube Placement No Better for Recurrent Otitis Media
THURSDAY, May 13, 2021 -- For young children with recurrent otitis media, the rate of episodes of acute otitis media is not significantly lower with tympanostomy-tube placement versus medical management during the ensuing two-year period, according to a study published in the May 13 issue of the New England Journal of Medicine.
Alejandro Hoberman, M.D., from the University of Pittsburgh School of Medicine, and colleagues randomly assigned children ages 6 to 35 months with recurrent acute otitis media to undergo tympanostomy-tube placement or receive medical management involving episodic antimicrobial treatment.
The researchers found that the rate of episodes of acute otitis media per child-year during a two-year period was 1.48 ± 0.08 and 1.56 ± 0.08 in the tympanostomy-tube and medical-management groups, respectively, in the intention-to-treat analysis (P = 0.66). In a per-protocol analysis, the corresponding episode rates were 1.47 ± 0.08 and 1.72 ± 0.11. Results were mixed among secondary outcomes in the main analysis. The time to first episode of acute otitis media, various episode-related clinical findings, and the percentage of children meeting specified criteria for treatment failure favored tympanostomy-tube placement, while children's cumulative number of days with otorrhea favored medical management.
"We found that tympanostomy-tube placement was not superior to medical management in reducing the rate of episodes of acute otitis media during the ensuing two-year period," the authors write.
One author disclosed financial ties to Kaizen Bioscience and holding patents, including one licensed to Kaizen Bioscience. A second author disclosed ties to Merck.
© 2021 HealthDay. All rights reserved.
Posted May 2021
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.